ICHM | Conference

New Therapies for T-Cell Lymphomas on the Horizon
February 28, 2017

There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.

Emerging Therapies in the Treatment of Multiple Myeloma
February 28, 2017

In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.

Novel Antibody-Based Therapies Emerge for AML
February 27, 2017

A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.

Frontline CLL Therapy: Changes in Paradigm
February 25, 2017

Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax.

Overview of Myeloproliferative Disorders
February 24, 2017

In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.

New Options for Treating AL Amyloidosis
February 23, 2017

New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.